A. Dasgupta (Kolkata (West Bengal), India), I. Pavord (Oxford (Oxfordshire), United Kingdom)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Derivation and validation of the subscales of the severe asthma questionnaire
R. Jones (Plymouth, United Kingdom), M. Hyland (Plymouth, United Kingdom), L. Joseph (Plymouth, United Kingdom), M. Masoli (Exeter, United Kingdom), A. Mansur (Birmingham, United Kingdom), A. Menzies-Gow (London, United Kingdom), S. Fowler (Manchester, United Kingdom), J. Dodd (Bristol, United Kingdom)
|   |
Use and reporting of health related quality of life questionnaires in severe asthma clinical trials
J. Lanario (Plymouth (Devon), United Kingdom), L. Burns (Plymouth (Devon), United Kingdom)
| |
A questionnaire to measure the extra-pulmonary symptoms of asthma
G. De Felice (Rome, Italy), M. Hyland (Plymouth, United Kingdom), J. Lanario (Plymouth, United Kingdom), Y. Antonacci (Palermo, Italy), R. Jones (Plymouth, United Kingdom), M. Masoli (Exeter, United Kingdom)
| |
Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score.
I. Veiga Teijeiro (Lugo, Spain), I. Guzmán Peralta (Lugo, Spain), L. Pérez De Llano (Lugo, Spain), I. Martín Robles (Lugo, Spain), N. Blanco Cid (Lugo, Spain), D. Dacal Rivas (Lugo, Spain), I. Davila (Salamanca, Spain), E. Martínez-Moragón (Valencia, Spain), J. Domínguez Ortega (Madrid, Spain), C. Almonacid (Madrid, Spain), C. Colás (Zaragoza, Spain), J. García-Rivero (Laredo, Spain), L. Carmona (Santiago de Compostela, Spain), M. García De Yébenes (Madrid, Spain), B. García-Cosío (Palma de Mallorca, Spain)
| |
Swiss Severe Asthma Registry (SSAR)- Good asthma control and high number of exacerbations. How does this fit?
F. Jaun (Liestal, Switzerland), J. Capponi (Liestal, Switzerland), A. Jochmann (Basel, Switzerland), N. Pavlov (Bern, Switzerland), L. Kern (St.Gallen, Switzerland), S. Widmer (St.Gallen, Switzerland), C. Clarenbach (Zürich, Switzerland), N. Sievi (Zürich, Switzerland), C. Steurer-Stey (Zürich, Switzerland), H. Duchna (Davos, Switzerland), T. Rothe (Chur, Switzerland), M. Dinic (Chur, Switzerland), C. Oberhänsli (Davos, Switzerland), P. Gianella (Lugano, Switzerland), M. Paronitti Lovera (Lugano, Switzerland), F. Charbonnier (Geneva, Switzerland), M. Salamin (Sion, Switzerland), P. Bridevaux (Sion, Switzerland), C. Von Garnier (Lausanne, Switzerland), J. Leuppi (Liestal, Switzerland)
| |
Low versus high Th2 asthma: variability of blood eosinophil counts in a longitudinal analysis
B. Patchett (Philadelphia, United States of America), G. Mavraj (Philadelphia, United States of America), B. Nriagu (Philadelphia, United States of America), R. Patel (Philadelphia, United States of America), E. Schulman (Philadelphia, United States of America)
| |
FeNO threshold used to select severe asthma patients for Dupilumab may be inappropriate>
J. COFINO CASANUEVA (Brussels, Belgium), A. Van Muylem (Brussels, Belgium), A. Haccuria (Brussels, Belgium), L. Demey (Brussels, Belgium), A. Michils (Brussels, Belgium)
| |
BREATHE – Distribution and co-expression of T2 biomarkers in asthma and association with severity, clinical characteristics and co-morbidities
D. Klein (København NV, Denmark), L. Frøssing (København NV, Denmark), G. Telg (Södertälje, Sweden), C. Porsbjerg (København NV, Denmark)
| |
Eosinophilic refractory inflammation in OCS-dependent severe asthma
V. Carriero (Orbassano, Italy), F. Bertolini (Orbasssano, Italy), E. Arrigo (Orbasssano, Italy), F. Ricciardolo (Orbassano, Italy)
| |
A proposal for standardization of the bronchial biopsy assessment in severe asthma
C. Gomez (Palma de Mallorca, Spain), H. Shafiek (Alexandria, Egypt), A. Iglesias (Palma de Mallorca, Spain), M. Iglesias (Barcelona, Spain), A. Gonzalez-Piñeiro (Vigo, Spain), M. Rodríguez (Salamanca, Spain), M. García-Cosío (Madrid, Spain), E. Busto (Lugo, Spain), J. Martin (Madrid, Spain), M. Saiz (Madrid, Spain), B. Paz (Madrid, Spain), A. Benito (Madrid, Spain), L. Mejías (Madrid, Spain), L. Lopez Vilaro (Barcelona, Spain), B. Cosio (Palma de Mallorca, Spain)
| |
Characterisation of severe, steroid-dependent asthma patients who initiate biologics versus those who do not
W. Chen (Vancouver, Canada), M. Sadatsafavi (Vancouver, Canada), L. Bulathsinhala (Singapore, Singapore), E. Garcia Gil (Gaithersburg, United States of America), T. Tran (Gaithersburg, United States of America), J. Fitzgerald (Vancouver, Canada), R. Murray (Singapore, Singapore), D. Price (Singapore, Singapore), I. Glitter Working Group (Singapore, Singapore)
| |
Baseline characteristics of severe asthma patients initiating biologic treatment worldwide
L. Pérez De Llano (Lugo, Spain), A. Cepelis (Singapore, Singapore), T. Tran (Gaithersburg, United States of America), R. Murray (OPRI, Singapore), D. Price (OPRI, Singapore), . Beam Working Group (OPRI, Singapore)
| |
Efficacy of azithromycin in a real world severe asthma cohort
A. Kumar (Liverpool, United Kingdom), S. Zaidi (Liverpool, United Kingdom), N. Fay (Liverpool, United Kingdom), T. Fitzmaurice (Liverpool, United Kingdom), A. Watkin (Liverpool, United Kingdom), H. Joplin (Liverpool, United Kingdom), H. Burhan (Liverpool, United Kingdom)
| |
Adapting asthma clinical trials in response to the COVID-19 pandemic - the BenRex study design
S. Smith (Glasgow, United Kingdom), L. Gillespie (Glasgow, United Kingdom), L. Heaney (Belfast, United Kingdom), C. Brightling (Leicester, United Kingdom), A. Mcconnachie (Glasgow, United Kingdom), S. Siddiqui (Lecester, United Kingdom), V. Mistry (Lecester, United Kingdom), V. Brown (Belfast, United Kingdom), D. Jackson (London, United Kingdom), N. Lee (Glasgow, United Kingdom), S. Fowler (Manchester, United Kingdom), A. Mansur (Birmingham, United Kingdom), H. Burhan (Liverpool, United Kingdom), D. Saralaya (Bradford, United Kingdom), R. Kurukulaaratchy (Southampton, United Kingdom), S. Nasser (Cambridge, United Kingdom), P. Pfeffer (London, United Kingdom), T. Brown (Portsmouth, United Kingdom), J. Lordan (Newcastle, United Kingdom), I. Pavord (Oxford, United Kingdom), R. Chaudhuri (Glasgow, United Kingdom)
| |
Inducible laryngeal obstruction in asthma
A. Rogde (Bergen, Norway), S. Lehmann (Bergen, Norway), H. Clemm (Bergen, Norway), O. Røksund (Bergen, Norway), H. Kvidaland (Bergen, Norway), T. Halvorsen (Bergen, Norway), M. Vollsaeter (Bergen, Norway), T. Andersen (Bergen, Norway)
| |
Detection of laryngeal dysfunction in the systematic assessment of severe asthma
J. Selby (London, United Kingdom), B. Cushen (London, United Kingdom), P. Patel (London, United Kingdom), R. Rauch (London, United Kingdom), J. Hull (London, United Kingdom)
| |
The burden of COPD in young individuals: results from EPISCAN II
B. García Cosío Piqueras (Palma de Mallorca, Spain), C. Casanova (Tenerife, Spain), J. Soriano (Madrid, Spain), I. Alfageme (Sevilla, Spain), M. Miravitlles (Barcelona, Spain), P. De Lucas (Madrid, Spain), J. Soler-Cataluña (Valencia, Spain), F. García-Río (Madrid, Spain), J. Rodriguez Gonzalez-Moro (Madrid, Spain), G. Sanchez-Herrero (Madrid, Spain), J. Ancochea (Madrid, Spain)
| |
Late Breaking Abstract - Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study
A. Menzies-Gow (London, United Kingdom), M. Gurnell (Cambridge, United Kingdom), L. Heaney (Belfast, United Kingdom), J. Corren (Los Angeles, United States of America), E. Bel (Amsterdam, Netherlands), J. Maspero (Buenos Aires, Argentina), T. Harrison (Nottingham, United Kingdom), D. Jackson (London, United Kingdom), D. Price (Singapore, Singapore), N. Lugogo (Ann Arbor, United States of America), J. Kreindler (Wilmington, United States of America), A. Burden (Cambridge, United Kingdom), A. De Giorgio-Miller (Luton, United Kingdom), K. Padilla (Durham, United States of America), U. Martin (Gaithersburg, United States of America), E. Garcia Gil (Barcelona, Spain)
| |
Late Breaking Abstract - Comparative Effectiveness of Anti-IL5/5R Versus Anti-IgE in Patients Eligible for Both (FIRE)
N. Ali (Singapore, Singapore), J. Lyu (Singapore, Singapore), A. Newell (Singapore, Singapore), M. Sadatsafavi (Vancouver, British Columbia, Canada), T. Tran (MD, United States of America), D. Price (Aberdeen, United Kingdom)
| |
Late Breaking Abstract - Standard-of-Care Asthma Controller Regimen Reduction with Benralizumab Treatment: ANDHI In Practice Study
R. Louis (Liège, Belgium), P. Chanez (Marseille, France), F. Menzella (Reggio Emilia, Italy), G. Philteos (Saskatchewan, Canada), B. Cosio (Palma de Mallorca, Spain), N. Lugogo (Ann Arbor, United States of America), G. De Luiz (Barcelona, Spain), T. Harrison (Nottingham , United Kingdom), A. Burden (Cambridge, United Kingdom), T. Adlington (Cambridge, United Kingdom), N. Keeling (Gothenburg, Sweden), J. Kwiatek (Wilmington, United States of America), E. Garcia Gil (Barcelona, Spain)
| |